Flerie publishes merger document for Biosergen merger
The document outlines the merger plan where Biosergen is absorbed into Flerie, with EGMs on August 6, 2026.
See the latest news and media coverage for Flerie. We track all announcements, press releases, and industry mentions in real time, all in one place.
Active long-term life science investor
flerie.comLast updated
In short: Flerie executed strategic growth through mergers with Lipum and Biosergen while reporting a net asset value of 3.4 billion SEK for Q2 2026.
The document outlines the merger plan where Biosergen is absorbed into Flerie, with EGMs on August 6, 2026.
Net profit was SEK -92 million, with portfolio fair value down 3.0% due to negative share price development in Xspray and Xintela.
The meeting, to be held on August 6, 2026, will decide on the merger plan and share issuance.
The peer-reviewed publication details first-in-human results from its portfolio company LIPUM AB.
Earnings call Flerie delivered a robust Q1 2026, raising SEK 208 million in new financing and achieving a 9% sequential increase in net asset value...
06:23 DNB Carnegie lowers Flerie's price target to 26 crowns (from 45), maintains buy recommendation FW 09/07 Flerie AB publishes its...
The adjusted net asset value per share of investment company Flerie fell to 39.14 crowns at the end of the second quarter, from 52.78 crowns a...
Close Morning Check: New wave of attacks in the Middle East - oil continues up. Morning's most important news with Noel Hermansson The investment company Flerie, focusing on biotechnology and pharmaceutical investments...
Track Flerie and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.